(MENAFN- GlobeNewsWire - Nasdaq) CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD,“Relmada” or the“Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.

Conference Call and Webcast Information:

• Date: Thursday, November 13, 2025 at 4:30 PM ET
• Participant Dial-in (US): 1-877-407-0792
• Participant Dial-in (International): 1-201-689-8263
• Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit

Investor Contact:
Brian Ritchie
LifeSci Advisors
...

Media Inquiries:
Corporate Communications
...

MENAFN07112025004107003653ID1110310637